tapentadol hydrochloride - Profile

What are the generic drug sources for tapentadol hydrochloride and what is the scope of freedom to operate?

Tapentadol hydrochloride is the generic ingredient in three branded drugs marketed by Collegium Pharm Inc, Novitium Pharma, Hikma, and Humanwell, and is included in six NDAs. There are two patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Tapentadol hydrochloride has fifty-one patent family members in twenty-two countries.

There are two tentative approvals for this compound.

Summary for tapentadol hydrochloride

International Patents:	51
US Patents:	2
Tradenames:	3
Applicants:	4
NDAs:	6
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for tapentadol hydrochloride

Generic filers with tentative approvals for TAPENTADOL HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 20MG BASE/ML	SOLUTION;ORAL
		100MG	TABLET;ORAL
		75MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for TAPENTADOL HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NUCYNTA	Oral Solution	tapentadol hydrochloride	20 mg/mL	203794	1	2013-12-20
NUCYNTA	Tablets	tapentadol hydrochloride	50 mg, 75 mg, and 100 mg	022304	4	2012-11-20
NUCYNTA ER	Extended-release Tablets	tapentadol hydrochloride	50 mg, 100 mg, 150 mg, 200 mg, and 250 mg	200533	2	2012-11-20

US Patents and Regulatory Information for tapentadol hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	SOLUTION;ORAL	203794-001	Oct 15, 2012		DISCN	Yes	No
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	SOLUTION;ORAL	203794-001	Oct 15, 2012		DISCN	Yes	No
Novitium Pharma	TAPENTADOL HYDROCHLORIDE	tapentadol hydrochloride	SOLUTION;ORAL	219119-001	Jan 26, 2026		RX	No	No
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-001	Aug 25, 2011		RX	Yes	No					Y
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-001	Aug 25, 2011		RX	Yes	No					Y
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-002	Aug 25, 2011		RX	Yes	No					Y
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-002	Aug 25, 2011		RX	Yes	No					Y

Expired US Patents for tapentadol hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-004	Aug 25, 2011
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-002	Aug 25, 2011
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-005	Aug 25, 2011
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-002	Aug 25, 2011
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-002	Aug 25, 2011
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-005	Aug 25, 2011
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-001	Aug 25, 2011

International Patents for tapentadol hydrochloride

Country	Patent Number	Title	Estimated Expiration
Japan	6081337
China	101730530
Croatia	P20140280
World Intellectual Property Organization (WIPO)	2008110323
Slovenia	2148670
Israel	201479	שימוש בטאפנטאדול להכנת תרופה לטיפול בכאב (Use of tapentadol for the manufacture of a medicament for the treatment of pain)
South Africa	200907355	Titration of tapentadol

Supplementary Protection Certificates for tapentadol hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0693475	C00693475/01	Switzerland		PRODUCT NAME: TAPENTADOL; REGISTRATION NO/DATE: SWISSMEDIC 60530 20110222
0693475	12C0016	France		PRODUCT NAME: TAPENTADOL SOUS FORME DE SA BASE LIBRE OU SOUS FORME D'UN DE SES SELS D'ACIDES ACCEPTABLES DU POINT DE VUE PHYSIOLOGIQUE; NAT. REGISTRATION NO/DATE: NL40884 20111003; FIRST REGISTRATION: DE - 76261.00.00 20100819
1439829	99 1-2011	Slovakia		PRODUCT NAME: TAPENTADOL; NAT. REGISTRATION NO/DATE: 65/0667-0674/10-S, 65/090-0697/10-S 20101012; FIRST REGISTRATION: DE 75043-75048.00.00, 76261-76270.00.00 20100819
1439829	C 2011 002	Romania		PRODUCT NAME: TAPENTADOL SAU O SARE ACCEPTABILA FARMACEUTIC AACESTUIA; NATIONAL AUTHORISATION NUMBER: RO 3279/2011/01 - RO 3279/2011/22; DATE OF NATIONAL AUTHORISATION: 20110228; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): DE 75.046; DATE OF FIRST AUTHORISATION IN EEA: 20100819
0693475	2011/010	Ireland		PRODUCT NAME: TAPENTADOL IN BASIC FORM OR IN THE FORM OF A SALT OF A PHYSIOLOGICALLY COMPATIBLE ACID, ESPECIALLY TAPENTADOL HYDROCHLORIDE; NAT REGISTRATION NO/DATE: PA1189/007/001-008 20101221; FIRST REGISTRATION NO/DATE: PA1189/008/001-008 21/12/2010 GERMANY 75043.00.00 75044.00.00 75045.00.00 19/08/2010 GERMANY 76261.00.00 76262.00.00 76263.00.00 76264.00.00 76265.00.00 19/08/2010 GERMANY 75046.00.00 75047.00.00 75048.00.00 19/08/2010 GERMANY 76266.00.00 76267.00.00 76268.00.0076269.00.00 76270.00.00 20100819
0693475	PA2011007	Lithuania		PRODUCT NAME: TAPENTADOLUM; NAT. REGISTRATION NO/DATE: LT/1/10/2341/001 - LT/1/10/2341/66, 2011 02 19; LT/1/10/2342/001 - LT/1/10/2342/110 20110219; FIRST REGISTRATION: 75043.00.00 - 75048.00.00, 2010 08 19; 76261.00.00 - 76270.00.00 20100819
0693475	PA2011007,C0693475	Lithuania		PRODUCT NAME: TAPENTADOLUM; NAT. REGISTRATION NO/DATE: LT/1/10/2341/001 - LT/1/10/2341/66, 2011 02 19; LT/1/10/2342/001 - LT/1/10/2342/110 20110219; FIRST REGISTRATION: 75043.00.00 - 75048.00.00, 2010 08 19; 76261.00.00 - 76270.00.00 20100819

Tapentadol Hydrochloride: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Tapentadol hydrochloride is a centrally acting opioid analgesic indicated primarily for moderate to severe pain management. Its unique mechanism of action—combining mu-opioid receptor activity with norepinephrine reuptake inhibition—sets it apart from traditional opioids. Its market landscape is evolving amidst regulatory scrutiny, opioid addiction concerns, and shifting prescription patterns, with significant opportunities linked to expanding indications and geographic penetration. This report analyzes the investment prospects, market drivers, competitive landscape, and financial forecastings for tapentadol hydrochloride over the next decade.

---

What Is the Current Market Landscape for Tapentadol Hydrochloride?

Market Size and Composition (2023)

Parameter	Value/Estimate	Notes
Global sales revenue	~$700 million	Estimated (Evaluated by IQVIA, 2022)
North America market share	~60%	Dominates due to high opioid prescribing and approval rates
Key competitors	Tramadol, oxycodone, fentanyl	For pain indications
Major formulations	Oral tablets, extended-release	For chronic pain management

Key Approved Uses & Off-Label Utilization

• Moderate to severe acute and chronic pain
• Potential off-label use for neuropathic pain
• Under investigation for fibromyalgia and osteoarthritis

Market Growth Drivers

• Rising prevalence of chronic pain conditions globally (WHO estimates 1.5 billion people affected)
• Increasing adoption in outpatient settings
• Expansion into new geographies (e.g., Asia-Pacific, Latin America)
• Potential label expansion for additional pain indications

---

What Are the Key Market Dynamics & Challenges?

Regulatory and Societal Factors

Factor	Impact
Opioid crisis and regulatory scrutiny	Tightening of prescribing guidelines, Risk ofmarket exit for some formulations
Reimbursement policies	Variable; reimbursement favors newer formulations with abuse-deterrent features
Generic penetration post-expiry	Significant price erosion and competitive pressure

Patent Status & Market Exclusivity

Patent/Regulatory Event	Impact
Patent expiry for specific formulations	Leads to increased generic competition
Market exclusivity for new formulations	Delays generic entry; strategic for revenue maintenance

Competitive Landscape Overview

Competitor	Product Name	Key Attributes	Market Share*
Tramadol (generic & Brand)	Ultram, ConZip	Weak opioid activity, less regulation	High
Oxycodone	OxyContin, Percocet	Powerful, high abuse potential	Significant
Fentanyl	Duragesic, Actiq	Delivery patches, high potency	High
Tapentadol (Brand: Nucynta)	Nucynta, Nucynta ER	Dual mechanism, abuse-deterrent formulations available	Moderate

*Market share data approximate, based on 2022 global sales estimates.

---

What Is the Financial Trajectory for Tapentadol?

Revenue Projections (2023–2030)

Year	Projected Revenue	Assumptions	Source/Methodology
2023	$700 million	Current sales, stable market share	Base case
2024	$750 million	Slight growth with new formulations, market expansion	CAGR 6-7%
2025	$820 million	Initiatives for broader indications and markets	Market expansion, new indications
2026	$900 million	Entering emerging markets with differentiated products	Geographic expansion
2027–2030	$950M–$1.2 billion	Patent cliffs, increased off-label use, potential settlement/approval of new formulations	Growth factors, patent expiry impacts

Key Revenue Drivers

• Launch of abuse-deterrent formulations (2018 FDA approval for Nucynta ER)
• Broadened indications (e.g., neuropathic pain, fibromyalgia)
• Gaining market share in Asia-Pacific and Latin America
• Transition to biosimilars and generics post-patent expiry (anticipated after 2025)

Cost Structure Considerations

• R&D investments for new formulations
• Regulatory compliance costs
• Manufacturing scale-up and quality assurance
• Marketing and education campaigns to physicians

---

How Do Regulatory Policies Impact Investment?

Policy Area	Impact	Notable Date/Policy
Opioid prescribing guidelines	Reduced prescription volumes, increased scrutiny	CDC guidelines 2016, updates 2022
Abuse-deterrent formulation mandates	Accelerates product reformulation, recalls	US FDA 2013, final guidance 2019
Patent law and exclusivity periods	Influence on generic market entry	Patent expiry for Nucynta ER expected 2025
International regulatory harmonization	Facilitates global expansion	ICH guidelines, EMA policies

---

Comparative Analysis: Tapentadol Hydrochloride vs. Competitive Agents

Attribute	Tapentadol	Tramadol	Oxycodone	Fentanyl
Mechanism of Action	Mu-opioid + NE reuptake	Weak opioid + serotonin	Strong opioid	Potent opioid with delivery options
Abuse Potential	Moderate	Low-moderate	High	Very high
Regulatory Stringency	Moderate to high	Moderate	High	Very high
Formulation diversity	Multiple (immediate, ER)	Immediate only	Immediate/ER	Patches, lozenges
Market Penetration	Growing	Mature	Mature	Mature

---

What Are the Key Opportunities and Risks?

Opportunities

• Expansion into new indications: Neuropathic pain, fibromyalgia, osteoarthritis.
• Growing markets: Asia-Pacific, Latin America, Eastern Europe.
• Drug delivery innovations: Abuse-deterrent formulations, transdermal patches.
• Regulatory approvals: Faster pathways via accelerated approval for new formulations or indications.
• Healthcare-driven digitization: Remote monitoring, telemedicine for pain management, expanding prescription footprint.

Risks

• Regulatory clampdowns: Further restrictions on opioid prescribing.
• Legal liabilities: Litigation related to opioid epidemic.
• Market saturation and commoditization: Post-patent expiration erosion.
• Public perception: Negative sentiment toward opioids impacts adoption.

---

Deep Dive: Strategic Considerations for Stakeholders

Stakeholder	Focus Areas	Strategic Moves
Pharmaceutical Companies	Innovation, regulatory strategy, portfolio diversification	Develop abuse-deterrent formulations, apply for new indications
Investors	Market growth, patent lifecycle, regulatory landscape	Monitor approval pipeline, geographical expansion plans
Healthcare Providers	Pain management efficacy, safety profiles	Prioritize patient safety, adopt new formulations cautiously
Regulators	Opioid misuse prevention, drug safety	Enforce stricter prescribing guidelines, promote abuse-deterrent technologies

---

Conclusion and Actionable Insights

• Investment viability: Tapentadol's dual mechanism and abuse-deterrent formulations position it as a competitive analgesic with growth potential. However, the impact of regulatory measures and patent expiries requires careful timing and portfolio management.
• Market expansion: Focus on emerging markets with rising chronic pain prevalence and less regulatory scrutiny.
• Pipeline development: Emphasize R&D for novel formulations, extended indications, and combination therapies to extend market relevance.
• Risk mitigation: Keep pace with regulatory updates, patent statuses, and societal attitudes towards opioid medications.
• Diversification: Consider supplementary investment in adjacent pain management innovations, such as non-opioid analgesics and digital health tools.

---

Key Takeaways

• Tapentadol hydrochloride is positioned for moderate growth but faces regulatory and competitive pressures.
• Market expansion hinges on regulatory pathways, geographic penetration, and indication growth.
• Patent expiration anticipated around 2025 could lead to price erosion, but formulations with abuse-deterrent features sustain revenue.
• The global pain management market is projected to grow at a CAGR of approximately 6% through 2030, offering opportunities for strategic investment.
• Continuous monitoring of regulatory policies, patent statuses, and market access environments is crucial for maximizing investment returns.

---

FAQs

1. What are the primary growth drivers for tapentadol hydrochloride?

The expansion of its approved indications, increased adoption in emerging markets, and the development of abuse-deterrent formulations primarily drive growth.

2. How does regulatory scrutiny affect tapentadol's market prospects?

Stricter opioid prescribing guidelines and abuse deterrent mandates can constrain sales, necessitating innovation and strategic positioning.

3. When is patent expiry expected, and what will be its effect?

Patent expiry for Nucynta ER is projected around 2025, likely leading to increased generic competition and revenue decline unless mitigated by new formulations.

4. How does tapentadol compare financially with its competitors?

It maintains a moderate market share with revenues around $700 million per year, facing stiff competition from generics and senior opioids but offering patents' exclusivity advantages with newer formulations.

5. What are the future opportunities for investors regarding tapentadol?

Emerging indications, market expansion into developing regions, and pipeline innovations such as abuse-deterrent formulations and combination therapies provide significant upside potential.

---

References

1. IQVIA. Global Pharmaceutical Market Trends 2022.
2. U.S. Food and Drug Administration. Abuse-Deterrent Opioids Guidance, 2019.
3. World Health Organization. Global Burden of Disease Study 2019.
4. FDA. Nucynta (Tapentadol) FDA Approvals and Labeling.
5. MarketWatch. Pain Management Drugs Market Forecasts, 2023.

---